DELANEY MARK E 4

What Happened Mark E. Delaney, SVP & Chief Commercial Officer of Quest Diagnostics (DGX), recorded a small acquisition on 2026-04-20: 37 shares purchased at $194.70 each for a total cost of about $7,204. This was an acquisition (a purchase), though modest in size.

Key Details

• Transaction date: 2026-04-20; Price: $194.70 per share; Total value: ~$7,204.
• Filing date (Form 4): 2026-04-24. The filing is marked "L" indicating it was reported late.
• Shares owned following the reported transaction: not provided in the information you supplied.
• Footnotes in the filing:
  • F1: refers to an award of restricted share units (RSUs).
  • F2: indicates shares were acquired under a dividend reinvestment plan (DRIP) and were eligible for deferred reporting on Form 5 under Rule 16a-6; the reporting person chose to report them early on this Form 4.
• No indication of a 10b5-1 plan, cashless exercise, gift, or tax-withholding sale in the provided details.

Context

• This is a small insider purchase. Purchases can be viewed as more informative than routine sales, but the size here is modest and may reflect dividend reinvestment or routine compensation settlement rather than a significant directional bet.
• The "L" late-report flag is a compliance detail — late filings can occur for administrative reasons but are worth noting for accuracy and regulatory transparency.